Why Is Divi's Betting Big on Peptides, and Is It the Next Big Opportunity in Pharma?
What if the next big opportunity in pharma isn't a new drug but the complex ingredients behind it? As global drugmakers race to develop advanced treatments, peptides are quietly emerging as a promising opportunity, opening new doors for companies that can manufacture them at scale.
One company looking to ride this wave is Divi's Laboratories . Known for its expertise in pharmaceutical manufacturing, Divi's is now ramping up its peptide capabilities to tap into growing global demand. But what makes peptides so special, and could this bet unlock the company's next phase of growth? With a market cap of Rs 2.93 lakh crore, the shares of Divis Laboratories Ltd are trading at Rs 11,054 and are trading at a PE of 86 compared to their industry's PE of 33. The shares have given a return of more than 130% in the last 5 years.
What Are Peptides?
Peptides are short chains of amino acids (building blocks of proteins). As a result, they have an integral role in biological regulation across the human body. They are now commonly used in modern medicine to treat disorders such as diabetes, obesity, hormonal issues and some cancers.
Peptide-based medicines are very targeted to affect particular biological processes. An example of this includes GLP-1 (glucagon-like peptide-1) drugs. These have become famous worldwide for being effective at treating diabetes and obesity. Some popular drugs include Ozempic and Wegovy, which were developed by Novo Nordisk.
As peptides can be difficult to manufacture, it involves using advanced technology, specialist equipment and strict controls. This has created a huge opportunity for pharmaceutical companies like Divi's Laboratories to develop capabilities to supply essential peptide components and fragments to drug makers around the world.
Also Read: Blackstone's ₹5,000 Cr Bet on This NBFC: What Makes Its Gold Loan Business So Attractive?
The GLP-1 Boom and Peptide Demand
The global pharmaceutical industry is experiencing a high demand for GLP-1 drugs (glucagon-like peptide-1) due to their increasing use in the treatment of diabetes and obesity. Blockbuster drugs including Ozempic, Wegovy and Mounjaro have raised awareness of the potential, and many pharmaceutical companies are investing in the production of these peptide-based therapeutics.
With demand increasing, there has been an increased search by pharmaceutical companies globally to partner with reliable manufacturers that can produce complex peptides on a large scale. This area requires specialist technology and processing, which provides an opportunity for those with great manufacturing capabilities.
This increasing demand is providing opportunities for CDMOs like Divi's Laboratories. In their Q2 FY27 earnings call, they mentioned there has been increasing interest from customers in manufacturing peptides, specifically peptide fragments. They are not just focusing on GLP-1 drugs but are working with customers across multiple indications. This means they are positioned well to take advantage of the increasing use of peptide-based medications.
Why Is Divi's Betting on Peptides?
Peptides will not be anything new to Divi's Laboratories, having built up close to two decades of experience in peptide chemistry. The business was originally set up to manufacture peptide building blocks but has since moved into supplying more complex peptide fragments. As a result of the increasing sophistication of treatment options from pharmaceutical companies across the globe, the company wants to leverage this experience to build long-term innovator manufacturing arrangements.
In a Q2 FY27 earnings call, CEO Dr Kiran S. Divi highlighted that they currently have approx 60-70 custom synthesis projects running at any one time. These range from Phase 2 and Phase 3 molecules, through to qualification and commercialisation. This gives the company opportunities to get involved in drug development.
Finally, the company is keen to build itself as one of the world's leading integrated peptide manufacturers. Management mentioned that the company will be among the top 3 players in the peptide space based on their future capacity. However, the company has not provided information about how much capacity they have for peptides overall, or what percentage of revenue this will contribute to the group, meaning it is difficult to determine how big of an opportunity this may be going forward.
Also Read: HUL, ITC & Marico Are Betting Big on Protein: Who Is Best Positioned to Ride India's Nutrition Boom?
Inside Divi's Peptide Expansion
Divi’s Laboratories is looking to significantly increase their peptide manufacturing capabilities. In Q2 FY27, management mentioned that they are putting in several 3000 Litre Solid Phase Peptide Synthesis (SPPS) lines. Additional capacities are also being added to accommodate customer programmes. Manufacture of complex long-chain peptide fragments can take up to one/two months, so they need multiple lines.
The company is investing to enhance their solid-phase and liquid-phase capabilities. Depending on customer needs, they will manufacture peptides through solid phase and liquid phase. Although the focus is currently on the solid phase, Divi also has well-established liquid phase manufacturing capabilities.
Looking at overall expansion, Divi will invest between 2000 crores +/- 20% per annum over the next couple of years. This will be between 1600 and 2400 crores per annum to increase manufacturing capacity, backwards integration and advanced technologies. Management haven’t mentioned how much will go towards peptides.
Divi's Competitive Advantage
One of the major advantages Divi's Laboratories has is having a vertically integrated production setup. Unlike others which are reliant on outsourcing, Divi's has several key inputs into their production such as protected amino acids, resins, tags and advanced peptide fragments in house. This vertical integration means they have more control over their raw materials, cost, quality and reliability.
The other advantage Divi has is increasing production bases. They have 22 blocks in Unit 1, 25 blocks in Unit 2 and 6 blocks in Unit 3, meaning they have a total number of 53 blocks. Only 3 of these blocks are specific to particular projects; however, the rest give them flexibility. Their Kakinada facility is helping with their vertical integration.
Divi also has strong relationships with global pharma companies. The longest relationship they have with a custom synthesis customer is around 30 years. With this plus their knowledge of complex chemistries, flexible manufacturing and reliable supply we could see them getting more specialised peptide manufacturing contracts.
Also Read: How Can Himadri's Carbon Nanotube Plant Be a Game Changer for the Company?
Custom Synthesis: A Growth Driver
Divi's Laboratories' custom synthesis business has emerged as a key growth driver with good demand from international pharma players. In H1FY27, Custom Synthesis alone contributed 62% of standalone sales for the company, whereas the generic business contributed 38%.
Custom Synthesis saw strong momentum with around a 50% increase YoY in H1FY27. As the company has commercial products in place along with validation batches for new projects, management revealed that there are three major capex ongoing which are moving closer to commercialisation. One is at the last stage, whereas the other two will move forward in the next few quarters.
The growth is also contributing well to the bottom line. In Q2FY27 the company generated a consolidated total income of Rs 3,770 crore, an increase of 32% YoY. Net profit rose sharply by around 64% to Rs 1,127 crore. With more projects moving into validation, custom synthesis is likely to be an important contributor to earnings going forward. However, the extent and timing will be dependent on customers and regulatory approvals.
Can Peptides Fuel Divi's Next Growth Phase?
Peptides provide a potentially significant growth driver for Divi's Laboratories in the future. The business has focused on winning innovative projects which will result in long-term recurring supply due to drug approval. The business has several validation programmes currently under way; during the Q2 FY27 earnings call, management noted that there are several peptide fragments currently in validation or qualification.
This can lead to commercial supplies if they are successfully validated. There was no mention of any timeframes or revenue expectations for their peptide portfolio. The business is investing in new technology, including flow chemistry and biocatalysis. They have also invested in facilities to allow multiple enzyme productions on a tonne scale. This should help improve efficiency and scalability. However, the true growth potential will come from how quickly they gain approval for their peptides and move into commercial production.
Also Read: PB Fintech Shareholders Guide: What The Q2 Call Admitted, What It Avoided And What Comes Next
Challenges and Future Outlook
Despite the exciting opportunities, there are some challenges associated with Divi's Laboratories' ambitions in the peptides space. This space can be quite complex, with specialist infrastructure, high investment and regulatory requirements. As competition increases amongst global CDMO players, the possibility of delayed drug approvals and uncertainty around demand may hinder growth. Divi's also faces increased raw material prices and potential issues with the global supply chain.
However, Divi's appears well placed to take advantage of increasing demand for complex APIs. It has strong manufacturing capabilities with good customer relationships and high investment into new technologies. The main thing to look at is how well they are able to turn their growing pipeline into contracts and therefore generate revenue.
Peptides have the potential to be a key driver for growth in the future for Divi's Laboratories. Whilst there is a large opportunity, it will be important that they are able to deliver and gain approval from customers. From an investor perspective this provides an interesting opportunity over the longer term; however, we need to see if the investments in this area translate into steady earnings growth in the coming years.